Uterine leiomyosarcoma which has not spread beyond the uterus is usually treated with surgery. Patients are then monitored and given chemotherapy only if the cancer returns. In this Gynecologic Oncology Group study, researchers want to see if giving chemotherapy after surgery but before the tumor returns can decrease the chance of recurrence.
Patients will be randomly assigned to one of two groups. Half of the patients will receive the anticancer drugs gemcitabine and docetaxel followed by the drug doxorubicin after surgery. These are drugs commonly used to treat recurrent leiomyosarcoma, but using them right after surgery for leiomyosarcoma that has not spread beyond the uterus is considered investigational. The other half of the patients will not receive chemotherapy after surgery and will be monitored with CT scans.